Abstract
Long-wavelength UVA (340–400 nm UVA-1) phototherapy has been reported to be effective in atopic dermatitis, localized scleroderma and T-cell-derived skin diseases. We retrospectively investigated 70 patients with acute cutaneous GVHD after allogeneic haematopoietic cell transplantation or donor lymphocyte infusion. Complete and partial responses with a median duration of 10 months were achieved in 49 (70%) and 17 (24.3%) patients, respectively. Overall, 47 (67.1%) patients were not treated with systemic steroids. Furthermore, immunosuppression could be tapered in 24 (34.3%) patients while they were receiving UVA-1 treatment. Responses were seen irrespective of age or type of conditioning. Treatment was very well tolerated. After a median follow-up of 18 (range 10–60) months, three patients developed epithelial skin neoplasia. We conclude that UVA-1 therapy is feasible, well tolerated and can be an effective treatment for acute GVHD of the skin, thereby avoiding the use of systemic steroids and/or allowing a more rapid tapering of systemic immunosuppression in a substantial number of patients. The results of this retrospective analysis warrant larger, prospective studies and the effectiveness of UVA-1 therapy should be compared with other established treatment modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deeg HJ, Antin JH . The clinical spectrum of acute graft-versus-host disease. Semin Hematol 2006; 43: 24–31.
Ferrara JL, Yanik G . Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. Clin Adv Hematol Oncol 2005; 3: 415–419, 428.
Xia G, Truitt RL, Johnson BD . Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006; 12: 397–407.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443–447.
Ringden O, Backman L, Lonnqvist B, Heimdahl A, Lindholm A, Bolme P et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41–51.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.
Chao NJ, Chen BJ . Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006; 43: 32–41.
Arai S, Vogelsang GB . Management of graft-versus-host disease. Blood Rev 2000; 14: 190–204.
Doney KC, Weiden PL, Storb R, Thomas ED . Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1–8.
Vogelsang GB, Lee L, Bensen-Kennedy DM . Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003; 54: 29–52.
Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J . Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005; 84: 681–685.
Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431.
Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 206–212.
Reinauer S, Lehmann P, Plewig G, Heyll A, Sohngen D, Holzle E . Photochemotherapy (PUVA) of acute graft-versus-host disease]. Hautarzt 1993; 44: 708–712.
Wiesmann A, Weller A, Lischka G, Klingebiel T, Kanz L, Einsele H . Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151–155.
Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM . Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008; 59: 1017–1030.
Simon JC, Pfieger D, Schopf E . Recent advances in phototherapy. Eur J Dermatol 2000; 10: 642–645.
Dawe RS . Ultraviolet A1 phototherapy. Br J Dermatol 2003; 148: 626–637.
Ambach A, Bonnekoh B, Gollnick H . UVA1 radiation (340–400 nm) interferes with the perforin-granule system of CD8hi+ cytotoxic T lymphocytes in vitro. J Photochem Photobiol B 2006; 82: 236–243.
Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186: 1763–1768.
Grewe M, Gyufko K, Schopf E, Krutmann J . Lesional expression of interferon-gamma in atopic eczema. Lancet 1994; 343: 25–26.
Krutmann J . Ultraviolet A radiation-induced immunomodulation: molecular and photobiological mechanims. Eur J Dermatol 1998; 8: 200–202.
Furio L, Berthier-Vergnes O, Ducarre B, Schmitt D, Peguet-Navarro J . UVA radiation impairs phenotypic and functional maturation of human dermal dendritic cells. J Invest Dermatol 2005; 125: 1032–1038.
Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK . Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515–519.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Dittmar HC, Pflieger D, Schopf E, Simon JC . UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis. Hautarzt 2001; 52: 423–427.
Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D . The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687–705.
Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394–403.
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.
Reddy P . Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003; 21: 149–161.
Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R et al. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation 2008; 86: 968–976.
de Gruijl FR . Photocarcinogenesis: UVA vs UVB radiation. Skin Pharmacol Appl Skin Physiol 2002; 15: 316–320.
Black HS, deGruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, deFabo EC et al. Photocarcinogenesis: an overview. J Photochem Photobiol B 1997; 40: 29–47.
Ikehata H, Kawai K, Komura J, Sakatsume K, Wang L, Imai M et al. UVA1 genotoxicity is mediated not by oxidative damage but by cyclobutane pyrimidine dimers in normal mouse skin. J Invest Dermatol 2008; 128: 2289–2296.
Jhappan C, Noonan FP, Merlino G . Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003; 22: 3099–3112.
Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108–112.
Geusau A, Dunkler D, Messeritsch E, Sandor N, Heidler G, Rodler S et al. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008; 47: 918–925.
Krebsregister Saarland, Gesundheitsberichterstattung (GBE) Saarland-Krebsregister, Präsident-Baltz-Straße 5, 66119 Saarbrücken, Germany. 2010. Ref Type: Generic.
Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.
Acknowledgements
We express our gratitude to all the physicians and nurses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Schlaak, M., Schwind, S., Wetzig, T. et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant 45, 1741–1748 (2010). https://doi.org/10.1038/bmt.2010.230
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.230
Keywords
This article is cited by
-
Understanding and treatment of cutaneous graft-versus-host-disease
Bone Marrow Transplantation (2023)
-
Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment
American Journal of Clinical Dermatology (2018)
-
Kutane Graft-versus-Host-Erkrankung
Der Hautarzt (2018)
-
Protection of the biconcave profile of human erythrocytes against osmotic damage by ultraviolet-A irradiation through membrane-cytoskeleton enhancement
Cell Death Discovery (2017)
-
Stellenwert der Stammzelltransplantation in der Therapie kutaner T‑Zell-Lymphome
Der Hautarzt (2017)